Review Article
No access
Published Online: 13 September 2010

Interleukin-28 and Interleukin-29: Novel Regulators of Skin Biology

Publication: Journal of Interferon & Cytokine Research
Volume 30, Issue Number 8

Abstract

The skin forms an essential barrier between the inside of an organism and the environment. In addition to its function in insulation, temperature regulation, and sensation, it protects the body against physical trauma, pathogens, UV radiation, and excessive water loss. Many processes necessary for maintaining the skin integrity, including antimicrobial/antiviral defense, wound healing, and removal of tumors, are regulated by cytokines. Accumulating results lead us to assume that interleukin (IL)-28 and IL-29, 2 novel members of the IL-10-interferon cytokine family, are important regulators of some of these processes. In the skin, IL-28 and IL-29 can be produced by virus-infected cells, maturing dendritic cells (DCs), and regulatory T-cells, and they mainly influence keratinocytes and melanocytes. In keratinocytes, IL-28 and IL-29 induce growth inhibition. Simultaneously, these cytokines increase the cellular synthesis of proteins that directly hinder virus replication and enhance the readiness to present viral antigens to immune cells. Further, IL-28 and IL-29 upregulate expression of viral and microbial sensing cellular receptors, including toll-like receptor (TLR)3, TLR2, and melanoma differentiation associated gene 5, and strengthen the cellular response to these receptors' ligands. Thereby, in the noninfected skin IL-28 and IL-29 enhance the capacity of keratinocytes to react to viral and microbial products and at least indirectly upregulate their inflammatory potential and innate immunity. IL-28 and IL-29 can act synergistically with other mediators secreted during DC maturation (eg, IL-20). In summary, IL-28/IL-29 may play an important role in the skin in the clearance of viral and microbial infections and in the removal of tumors.

Get full access to this article

View all available purchase options and get full access to this article.

References

Ank NIversen MBBartholdy CStaeheli PHartmann RJensen UBDagnaes-Hansen FThomsen ARChen ZHaugen HKlucher KPaludan SR2008. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activityJ Immunol18042474-2485. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, Dagnaes-Hansen F, Thomsen AR, Chen Z, Haugen H, Klucher K, Paludan SR. 2008. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 180(4):2474–2485.
Ank NWest HPaludan SR2006. IFN-lambda: novel antiviral cytokinesJ Interferon Cytokine Res266373-379. Ank N, West H, Paludan SR. 2006. IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res 26(6):373–379.
Bartlett NWButtigieg KKotenko SVSmith GL2005. Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection modelJ Gen Virol86Pt 61589-1596. Bartlett NW, Buttigieg K, Kotenko SV, Smith GL. 2005. Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J Gen Virol 86(Pt 6):1589–1596.
Bin LHowell MDKim BEHall CFStreib JELeung DY2009. Inhibition of S100A11 gene expression impairs keratinocyte response against vaccinia virus through downregulation of the IL-10 receptor 2 chainJ Allergy Clin Immunol1242270-277277.e1. Bin L, Howell MD, Kim BE, Hall CF, Streib JE, Leung DY. 2009. Inhibition of S100A11 gene expression impairs keratinocyte response against vaccinia virus through downregulation of the IL-10 receptor 2 chain. J Allergy Clin Immunol 124(2):270–277, 277.e1.
Bonjardim CAFerreira PCKroon EG2009. Interferons: signaling, antiviral and viral evasionImmunol Lett12211-11. Bonjardim CA, Ferreira PC, Kroon EG. 2009. Interferons: signaling, antiviral and viral evasion. Immunol Lett 122(1):1–11.
Braff MHDi Nardo AGallo RL2005. Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodiesJ Invest Dermatol1242394-400. Braff MH, Di Nardo A, Gallo RL. 2005. Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. J Invest Dermatol 124(2):394–400.
Candi ESchmidt RMelino G2005. The cornified envelope: a model of cell death in the skinNat Rev Mol Cell Biol64328-340. Candi E, Schmidt R, Melino G. 2005. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol 6(4):328–340.
Chen HXu ZPeng LFang XYin XXu NCen P2006. Recent advances in the research and development of human defensinsPeptides274931-940. Chen H, Xu Z, Peng L, Fang X, Yin X, Xu N, Cen P. 2006. Recent advances in the research and development of human defensins. Peptides 27(4):931–940.
Chi BDickensheets HLSpann KMAlston MALuongo CDumoutier LHuang JRenauld JCKotenko SVRoederer MBeeler JADonnelly RPCollins PLRabin RL2006. Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virusJ Virol80105032-5040. Chi B, Dickensheets HL, Spann KM, Alston MA, Luongo C, Dumoutier L, Huang J, Renauld JC, Kotenko SV, Roederer M, Beeler JA, Donnelly RP, Collins PL, Rabin RL. 2006. Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J Virol 80(10):5032–5040.
Chiller KSelkin BAMurakawa GJ2001. Skin microflora and bacterial infections of the skinJ Investig Dermatol Symp Proc63170-174. Chiller K, Selkin BA, Murakawa GJ. 2001. Skin microflora and bacterial infections of the skin. J Investig Dermatol Symp Proc 6(3):170–174.
Coccia EMSevera MGiacomini EMonneron DRemoli MEJulkunen ICella MLande RUze G2004. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cellsEur J Immunol343796-805. Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, Julkunen I, Cella M, Lande R, Uze G. 2004. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 34(3):796–805.
Dai JMegjugorac NJGallagher GEYu RYGallagher G2009. IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cellsBlood113235829-5838. Dai J, Megjugorac NJ, Gallagher GE, Yu RY, Gallagher G. 2009. IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood 113(23):5829–5838.
De Benedetto AAgnihothri RMcGirt LYBankova LGBeck LA2009. Atopic dermatitis: a disease caused by innate immune defects?J Invest Dermatol129114-30. De Benedetto A, Agnihothri R, McGirt LY, Bankova LG, Beck LA. 2009. Atopic dermatitis: a disease caused by innate immune defects? J Invest Dermatol 129(1):14–30.
De Smedt TPajak BMuraille ELespagnard LHeinen EDe Baetselier PUrbain JLeo OMoser M1996. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivoJ Exp Med18441413-1424. De Smedt T, Pajak B, Muraille E, Lespagnard L, Heinen E, De Baetselier P, Urbain J, Leo O, Moser M. 1996. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med 184(4):1413–1424.
Doyle SESchreckhise HKhuu-Duong KHenderson KRosler RStorey HYao LLiu HBarahmand-pour FSivakumar PChan CBirks CFoster DClegg CHWietzke-Braun PMihm SKlucher KM2006. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytesHepatology444896-906. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, Yao L, Liu H, Barahmand-pour F, Sivakumar P, Chan C, Birks C, Foster D, Clegg CH, Wietzke-Braun P, Mihm S, Klucher KM. 2006. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44(4):896–906.
Dumoutier LLejeune DHor SFickenscher HRenauld JC2003. Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3Biochem J370Pt 2391-396. Dumoutier L, Lejeune D, Hor S, Fickenscher H, Renauld JC. 2003. Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3. Biochem J 370(Pt 2):391–396.
Dumoutier LTounsi AMichiels TSommereyns CKotenko SVRenauld JC2004. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signalingJ Biol Chem2793132269-32274. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC. 2004. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 279(31):32269–32274.
Gad HHDellgren CHamming OJVends SPaludan SRHartmann R2009. Interferon-{lambda} is functionally an interferon but structurally related to the interleukin-10 familyJ Biol Chem2843120869-20875. Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R. 2009. Interferon-{lambda} is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem 284(31):20869–20875.
Garcia JRJaumann FSchulz SKrause ARodriguez-Jimenez JForssmann UAdermann KKluver EVogelmeier CBecker DHedrich RForssmann WGBals R2001. Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattractionCell Tissue Res3062257-264. Garcia JR, Jaumann F, Schulz S, Krause A, Rodriguez-Jimenez J, Forssmann U, Adermann K, Kluver E, Vogelmeier C, Becker D, Hedrich R, Forssmann WG, Bals R. 2001. Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res 306(2):257–264.
Glaser RHarder JLange HBartels JChristophers ESchroder JM2005. Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infectionNat Immunol6157-64. Glaser R, Harder J, Lange H, Bartels J, Christophers E, Schroder JM. 2005. Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. Nat Immunol 6(1):57–64.
Harder JBartels JChristophers ESchroder JM1997. A peptide antibiotic from human skinNature3876636861. Harder J, Bartels J, Christophers E, Schroder JM. 1997. A peptide antibiotic from human skin. Nature 387(6636):861.
Harder JBartels JChristophers ESchroder JM2001. Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibioticJ Biol Chem27685707-5713. Harder J, Bartels J, Christophers E, Schroder JM. 2001. Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 276(8):5707–5713.
Harder JSchroder JM2005. Psoriatic scales: a promising source for the isolation of human skin-derived antimicrobial proteinsJ Leukoc Biol774476-486. Harder J, Schroder JM. 2005. Psoriatic scales: a promising source for the isolation of human skin-derived antimicrobial proteins. J Leukoc Biol 77(4):476–486.
Hornung VRothenfusser SBritsch SKrug AJahrsdorfer BGiese TEndres SHartmann G2002. Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotidesJ Immunol16894531-4537. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G. 2002. Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168(9):4531–4537.
Iversen MBAnk NMelchjorsen JPaludan SR2010. Expression of type III IFN in the vaginal mucosa is mediated primarily by DCs and displays stronger dependence on NF-{kappa}B than type I IFNsJ Virol8494579-4586. Iversen MB, Ank N, Melchjorsen J, Paludan SR. 2010. Expression of type III IFN in the vaginal mucosa is mediated primarily by DCs and displays stronger dependence on NF-{kappa}B than type I IFNs. J Virol 84(9):4579–4586.
Iwasaki AMedzhitov R2010. Regulation of adaptive immunity by the innate immune systemScience3275963291-295. Iwasaki A, Medzhitov R. 2010. Regulation of adaptive immunity by the innate immune system. Science 327(5963):291–295.
Jordan WJEskdale JBoniotto MRodia MKellner DGallagher G2007a. Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29)Genes Immun8113-20. Jordan WJ, Eskdale J, Boniotto M, Rodia M, Kellner D, Gallagher G. 2007a. Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun 8(1):13–20.
Jordan WJEskdale JSrinivas SPekarek VKelner DRodia MGallagher G2007b. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 responseGenes Immun83254-261. Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, Rodia M, Gallagher G. 2007b. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun 8(3):254–261.
Kirkwood JMTarhini AAPanelli MCMoschos SJZarour HMButterfield LHGogas HJ2008. Next generation of immunotherapy for melanomaJ Clin Oncol26203445-3455. Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, Gogas HJ. 2008. Next generation of immunotherapy for melanoma. J Clin Oncol 26(20):3445–3455.
Kotenko SVGallagher GBaurin VVLewis-Antes AShen MShah NKLanger JASheikh FDickensheets HDonnelly RP2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complexNat Immunol4169-77. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4(1):69–77.
Kunz SWolk KWitte EWitte KDoecke WDVolk HDSterry WAsadullah KSabat R2006. Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILsExp Dermatol1512991-1004. Kunz S, Wolk K, Witte E, Witte K, Doecke WD, Volk HD, Sterry W, Asadullah K, Sabat R. 2006. Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol 15(12):991–1004.
Lasfar ALewis-Antes ASmirnov SVAnantha SAbushahba WTian BReuhl KDickensheets HSheikh FDonnelly RPRaveche EKotenko SV2006. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanomaCancer Res6684468-4477. Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, Tian B, Reuhl K, Dickensheets H, Sheikh F, Donnelly RP, Raveche E, Kotenko SV. 2006. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res 66(8):4468–4477.
Li QKawamura KMa GIwata FNumasaki MSuzuki NShimada HTagawa M2010. Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agentsEur J Cancer461180-190. Li Q, Kawamura K, Ma G, Iwata F, Numasaki M, Suzuki N, Shimada H, Tagawa M. 2010. Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents. Eur J Cancer 46(1):180–190.
Liu AYDestoumieux DWong AVPark CHValore EVLiu LGanz T2002. Human beta-defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiationJ Invest Dermatol1182275-281. Liu AY, Destoumieux D, Wong AV, Park CH, Valore EV, Liu L, Ganz T. 2002. Human beta-defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiation. J Invest Dermatol 118(2):275–281.
MacPherson GGJenkins CDStein MJEdwards C1995. Endotoxin-mediated dendritic cell release from the intestine. Characterization of released dendritic cells and TNF dependenceJ Immunol15431317-1322. MacPherson GG, Jenkins CD, Stein MJ, Edwards C. 1995. Endotoxin-mediated dendritic cell release from the intestine. Characterization of released dendritic cells and TNF dependence. J Immunol 154(3):1317–1322.
Madison KC2003. Barrier function of the skin: “la raison d'etre” of the epidermisJ Invest Dermatol1212231-241. Madison KC. 2003. Barrier function of the skin: “la raison d'etre” of the epidermis. J Invest Dermatol 121(2):231–241.
Maher SGSheikh FScarzello AJRomero-Weaver ALBaker DPDonnelly RPGamero AM2008. IFN-alpha and IFN-lambda differ in their antiproliferative effects and duration of JAK/STAT signaling activityCancer Biol Ther771109-1115. Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP, Gamero AM. 2008. IFN-alpha and IFN-lambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther 7(7):1109–1115.
Manicassamy SPulendran B2009. Modulation of adaptive immunity with Toll-like receptorsSemin Immunol214185-193. Manicassamy S, Pulendran B. 2009. Modulation of adaptive immunity with Toll-like receptors. Semin Immunol 21(4):185–193.
Manoury BHewitt EWMorrice NDando PMBarrett AJWatts C1998. An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentationNature3966712695-699. Manoury B, Hewitt EW, Morrice N, Dando PM, Barrett AJ, Watts C. 1998. An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature 396(6712):695–699.
Marcello TGrakoui ABarba-Spaeth GMachlin ESKotenko SVMacDonald MRRice CM2006. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kineticsGastroenterology13161887-1898. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, Rice CM. 2006. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131(6):1887–1898.
Mempel MVoelcker VKollisch GPlank CRad RGerhard MSchnopp CFraunberger PWalli AKRing JAbeck DOllert M2003. Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependentJ Invest Dermatol12161389-1396. Mempel M, Voelcker V, Kollisch G, Plank C, Rad R, Gerhard M, Schnopp C, Fraunberger P, Walli AK, Ring J, Abeck D, Ollert M. 2003. Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. J Invest Dermatol 121(6):1389–1396.
Mennechet FJUze G2006. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cellsBlood107114417-4423. Mennechet FJ, Uze G. 2006. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 107(11):4417–4423.
Michalek MGelhaus CHecht OPodschun RSchroder JMLeippe MGrotzinger J2009. The human antimicrobial protein psoriasin acts by permeabilization of bacterial membranesDev Comp Immunol336740-746. Michalek M, Gelhaus C, Hecht O, Podschun R, Schroder JM, Leippe M, Grotzinger J. 2009. The human antimicrobial protein psoriasin acts by permeabilization of bacterial membranes. Dev Comp Immunol 33(6):740–746.
Miller DMKlucher KMFreeman JAHausman DFFontana DWilliams DE2009. Interferon lambda as a potential new therapeutic for hepatitis CAnn NY Acad Sci118280-87. Miller DM, Klucher KM, Freeman JA, Hausman DF, Fontana D, Williams DE. 2009. Interferon lambda as a potential new therapeutic for hepatitis C. Ann NY Acad Sci 1182:80–87.
Miller LS2008. Toll-like receptors in skinAdv Dermatol2471-87. Miller LS. 2008. Toll-like receptors in skin. Adv Dermatol 24:71–87.
Naka KTakemoto KAbe KDansako HIkeda MShimotohno KKato N2005. Interferon resistance of hepatitis C virus replicon-harbouring cells is caused by functional disruption of type I interferon receptorsJ Gen Virol86Pt 102787-2792. Naka K, Takemoto K, Abe K, Dansako H, Ikeda M, Shimotohno K, Kato N. 2005. Interferon resistance of hepatitis C virus replicon-harbouring cells is caused by functional disruption of type I interferon receptors. J Gen Virol 86(Pt 10):2787–2792.
Oren AGanz TLiu LMeerloo T2003. In human epidermis, beta-defensin 2 is packaged in lamellar bodiesExp Mol Pathol742180-182. Oren A, Ganz T, Liu L, Meerloo T. 2003. In human epidermis, beta-defensin 2 is packaged in lamellar bodies. Exp Mol Pathol 74(2):180–182.
Oyoshi MKHe RKumar LYoon JGeha RS2009. Cellular and molecular mechanisms in atopic dermatitisAdv Immunol102135-226. Oyoshi MK, He R, Kumar L, Yoon J, Geha RS. 2009. Cellular and molecular mechanisms in atopic dermatitis. Adv Immunol 102:135–226.
Pagliaccetti NEEduardo RKleinstein SHMu XJBandi PRobek MD2008. Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replicationJ Biol Chem2834430079-30089. Pagliaccetti NE, Eduardo R, Kleinstein SH, Mu XJ, Bandi P, Robek MD. 2008. Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J Biol Chem 283(44):30079–30089.
Pekarek VSrinivas SEskdale JGallagher G2007. Interferon lambda-1 (IFN-lambda1/IL-29) induces ELR(−) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-gamma-independent mannerGenes Immun82177-180. Pekarek V, Srinivas S, Eskdale J, Gallagher G. 2007. Interferon lambda-1 (IFN-lambda1/IL-29) induces ELR(−) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-gamma-independent manner. Genes Immun 8(2):177–180.
Proksch EBrandner JMJensen JM2008. The skin: an indispensable barrierExp Dermatol17121063-1072. Proksch E, Brandner JM, Jensen JM. 2008. The skin: an indispensable barrier. Exp Dermatol 17(12):1063–1072.
Robak T2006. Current treatment options in hairy cell leukemia and hairy cell leukemia variantCancer Treat Rev325365-376. Robak T. 2006. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat Rev 32(5):365–376.
Sa SMValdez PAWu JJung KZhong FHall LKasman IWiner JModrusan ZDanilenko DMOuyang W2007. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasisJ Immunol17842229-2240. Sa SM, Valdez PA, Wu J, Jung K, Zhong F, Hall L, Kasman I, Winer J, Modrusan Z, Danilenko DM, Ouyang W. 2007. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 178(4):2229–2240.
Sabat RPhilipp SHoflich CKreutzer SWallace EAsadullah KVolk HDSterry WWolk K2007a. Immunopathogenesis of psoriasisExp Dermatol1610779-798. Sabat R, Philipp S, Hoflich C, Kreutzer S, Wallace E, Asadullah K, Volk HD, Sterry W, Wolk K. 2007a. Immunopathogenesis of psoriasis. Exp Dermatol 16(10):779–798.
Sabat RWallace EEndesfelder SWolk K2007b. IL-19 and IL-20: two novel cytokines with importance in inflammatory diseasesExpert Opin Ther Targets115601-612. Sabat R, Wallace E, Endesfelder S, Wolk K. 2007b. IL-19 and IL-20: two novel cytokines with importance in inflammatory diseases. Expert Opin Ther Targets 11(5):601–612.
Sato AOhtsuki MHata MKobayashi EMurakami T2006. Antitumor activity of IFN-lambda in murine tumor modelsJ Immunol176127686-7694. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T. 2006. Antitumor activity of IFN-lambda in murine tumor models. J Immunol 176(12):7686–7694.
Schreml SSzeimies RMKarrer SHeinlin JLandthaler MBabilas P2009. The impact of the pH value on skin integrity and cutaneous wound healingJ Eur Acad Dermatol Venereol244373-378. Schreml S, Szeimies RM, Karrer S, Heinlin J, Landthaler M, Babilas P. 2009. The impact of the pH value on skin integrity and cutaneous wound healing. J Eur Acad Dermatol Venereol 24(4):373–378.
Sheppard PKindsvogel WXu WHenderson KSchlutsmeyer SWhitmore TEKuestner RGarrigues UBirks CRoraback JOstrander CDong DShin JPresnell SFox BHaldeman BCooper ETaft DGilbert TGrant FJTackett MKrivan WMcKnight GClegg CFoster DKlucher KM2003. IL-28, IL-29 and their class II cytokine receptor IL-28RNat Immunol4163-68. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4(1):63–68.
Siebler JWirtz SWeigmann BAtreya ISchmitt EKreft AGalle PRNeurath MF2007. IL-28A is a key regulator of T-cell-mediated liver injury via the T-box transcription factor T-betGastroenterology1321358-371. Siebler J, Wirtz S, Weigmann B, Atreya I, Schmitt E, Kreft A, Galle PR, Neurath MF. 2007. IL-28A is a key regulator of T-cell-mediated liver injury via the T-box transcription factor T-bet. Gastroenterology 132(1):358–371.
Sievert W2002. Management issues in chronic viral hepatitis: hepatitis CJ Gastroenterol Hepatol174415-422. Sievert W. 2002. Management issues in chronic viral hepatitis: hepatitis C. J Gastroenterol Hepatol 17(4):415–422.
Sommereyns CPaul SStaeheli PMichiels T2008. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivoPLoS Pathog43e1000017. Sommereyns C, Paul S, Staeheli P, Michiels T. 2008. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4(3):e1000017.
Weinstock-Guttman BRamanathan MZivadinov R2008. Interferon-beta treatment for relapsing multiple sclerosisExpert Opin Biol Ther891435-1447. Weinstock-Guttman B, Ramanathan M, Zivadinov R. 2008. Interferon-beta treatment for relapsing multiple sclerosis. Expert Opin Biol Ther 8(9):1435–1447.
Witte KGruetz GVolk HDLooman ACAsadullah KSterry WSabat RWolk K2009. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokinesGenes Immun108702-714. Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K. 2009. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 10(8):702–714.
Witte KWitte ESabat RWolk K2010. IL-28A, IL-28B and IL-29: promising cytokines with type I interferon like propertiesCytokine Growth Factor Rev214[in press]. Witte K, Witte E, Sabat R, Wolk K. 2010. IL-28A, IL-28B and IL-29: promising cytokines with type I interferon like properties. Cytokine Growth Factor Rev 21(4) [in press].
Wolk KGrutz GWitte KVolk HDSabat R2005. The expression of legumain, an asparaginyl endopeptidase that controls antigen processing, is reduced in endotoxin-tolerant monocytesGenes Immun65452-456. Wolk K, Grutz G, Witte K, Volk HD, Sabat R. 2005. The expression of legumain, an asparaginyl endopeptidase that controls antigen processing, is reduced in endotoxin-tolerant monocytes. Genes Immun 6(5):452–456.
Wolk KKunz SAsadullah KSabat R2002. Cutting edge: immune cells as sources and targets of the IL-10 family members?J Immunol168115397-5402. Wolk K, Kunz S, Asadullah K, Sabat R. 2002. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 168(11):5397–5402.
Wolk KKunz SWitte EFriedrich MAsadullah KSabat R2004. IL-22 increases the innate immunity of tissuesImmunity212241-254. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. 2004. IL-22 increases the innate immunity of tissues. Immunity 21(2):241–254.
Wolk KSabat R2006. Interleukin-22: A novel T- and NK-cell derived cytokine that regulates the biology of tissue cellsCytokine Growth Factor Rev175367-380. Wolk K, Sabat R. 2006. Interleukin-22: A novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 17(5):367–380.
Wolk KWitte EWallace EDocke WDKunz SAsadullah KVolk HDSterry WSabat R2006. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasisEur J Immunol3651309-1323. Wolk K, Witte E, Wallace E, Docke WD, Kunz S, Asadullah K, Volk HD, Sterry W, Sabat R. 2006. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 36(5):1309–1323.
Wolk KWitte KWitte EProesch SSchulze-Tanzil GNasilowska KThilo JAsadullah KSterry WVolk HDSabat R2008. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytesJ Leukoc Biol8351181-1193. Wolk K, Witte K, Witte E, Proesch S, Schulze-Tanzil G, Nasilowska K, Thilo J, Asadullah K, Sterry W, Volk HD, Sabat R. 2008. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol 83(5):1181–1193.
Zeeuwen PLCheng TSchalkwijk J2009. The biology of cystatin M/E and its cognate target proteasesJ Invest Dermatol12961327-1338. Zeeuwen PL, Cheng T, Schalkwijk J. 2009. The biology of cystatin M/E and its cognate target proteases. J Invest Dermatol 129(6):1327–1338.
Zhou ZHamming OJAnk NPaludan SRNielsen ALHartmann R2007. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinasesJ Virol81147749-7758. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. 2007. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 81(14):7749–7758.

Information & Authors

Information

Published In

cover image Journal of Interferon & Cytokine Research
Journal of Interferon & Cytokine Research
Volume 30Issue Number 8August 2010
Pages: 617 - 628
PubMed: 20712456

History

Published online: 13 September 2010
Published in print: August 2010
Accepted: 8 June 2010
Received: 8 June 2010

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

Kerstin Wolk
Interdisciplinary Department of Molecular Immunopathology, Dermatology/Medical Immunology, University Hospital Charité, Berlin, Germany.
Katrin Witte
Interdisciplinary Department of Molecular Immunopathology, Dermatology/Medical Immunology, University Hospital Charité, Berlin, Germany.
Robert Sabat
Interdisciplinary Department of Molecular Immunopathology, Dermatology/Medical Immunology, University Hospital Charité, Berlin, Germany.

Notes

Address correspondence to:Dr. Kerstin WolkInterdisciplinary Department of Molecular Immunopathology,Dermatology/Medical ImmunologyUniversity Hospital Charité, CCM10117 BerlinGermany
E-mail: [email protected]

Author Disclosure Statement

No competing financial interests exist.

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/ePub

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media

Back to Top